Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An anti-tumor targeting complex and a preparation method and applications thereof

A targeting complex, anti-tumor technology, applied in anti-tumor drugs, chemical instruments and methods, hybrid peptides, etc., can solve problems such as insufficient killing of tumor cells and failure to achieve anti-tumor effects

Active Publication Date: 2013-09-11
SHANGHAI TONEKER BIOTECH
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, although CTX has tumor targeting, it is not enough to kill tumor cells; although Onc can kill tumor cells, it can also kill normal cells, and has no selective killing effect on tumor cells.
Even the combination of Onc and CTX does not achieve good anti-tumor effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An anti-tumor targeting complex and a preparation method and applications thereof
  • An anti-tumor targeting complex and a preparation method and applications thereof
  • An anti-tumor targeting complex and a preparation method and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Example 1: Recombinant expression of mature CTX in Escherichia coli

[0024] Induced expression and isolation and purification of GST-6×His-CTX: The gene encoding the CTX precursor carrying 6×His tag and enterokinase cleavage site at the N-terminus was synthesized by chemical method, using E. coli preferred codons (Seq ID NO .1). The chemically synthesized gene was cloned into the Escherichia coli expression vector pGEX-4T-1, and confirmed by DNA sequencing. The expression vector pGEX-4T-1 / 6×His-CTX was transformed into Escherichia coli BL21(DE3), and its expression was induced by IPTG in TB medium (cultured overnight at 16°C). The bacteria were collected by centrifugation and resuspended in lysis buffer (50mmol / l phosphate, 0.5mol / l NaCl, pH 7.5). The bacteria were broken by pressure method, and DNase I was added to degrade DNA. Then add solid sodium sulfite to a final concentration of 0.2 mol / L, add solid sodium tetrathionate to a final concentration of 0.15 mol / L, ...

Embodiment 2

[0026] Example 2: Recombinant expression of mature Onc in Escherichia coli

[0027] 6×His-Onc induced expression and isolation and purification: The Onc gene carrying 6×His tag at the N-terminus was synthesized by chemical method, and the preferred codon of E. coli was selected (Seq ID NO.3). The gene was ligated into the expression vector pET and confirmed by DNA sequencing. Then the expression vector pET / 6×His-Onc was transformed into Escherichia coli BL21(DE3), and the expression was induced with IPTG in TB medium at 37°C. The bacteria were disrupted by ultrasonic method, and the inclusion bodies were collected by centrifugation. The inclusion bodies were dissolved with 6 mol / l guanidine hydrochloride, and the final concentration of 0.2 mol / l sodium sulfite and 0.15 mol / l sodium tetrathionate was added to reversibly modify the sulfhydryl group in Onc. After shaking slowly at room temperature for 2-3h, the sulfonated 6×His-Onc was purified by metal chelate chromatography, ...

Embodiment 3

[0029] Example 3: Chemical crosslinking of CTX and Onc

[0030]The mature CTX recombinantly prepared in Example 1 and the amino-specific modifier SPDP were reacted in phosphate buffer (50mmol / l sodium phosphate, 150mmol / l NaCl, pH8.0) at room temperature for 1 hour at a molar ratio of 1:1, and then Adjusted to pH 3.0 with TFA, purified by HPLC, and the modified CTX was collected and identified by mass spectrometry. The mature Onc prepared recombinantly in Example 2 and the amino-specific modifier 2-Iminothiolane were mixed in phosphate buffer (50mmol / l sodium phosphate, 150mmol / l NaCl, 2.4mmol / l mercaptoethanol, pH8.0) at a ratio of 1:20 The molar ratio was reacted at room temperature for 1 h, then the pH was adjusted to 3.0 with acetic acid, and the excess modifier was removed with Sephadex G-25 molecular sieve. The above-mentioned modified CTX and modified Onc were reacted at room temperature for 0.5 h in phosphate buffer (50 mmol / l sodium phosphate, 150 mmol / l NaCl, pH 8.0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an anti-tumor targeting complex which is a chemical crosslinked complex CTX-Onc obtained from chlorotoxin and onconase through disulfide bond crosslinking. Compared with existing anti-tumor CTX and Onc mixtures, the anti-tumor targeting complex of the invention shows better anti-tumor effects both at a cellular level and an animal tumor model level, and has good clinical application and development prospects. The invention also provides a method for preparing the complex and applications of the complex in the preparation of antitumor drugs.

Description

technical field [0001] The invention relates to the field of biopharmaceuticals related to biochemistry and genetic engineering technology. Specifically, the invention relates to an anti-tumor targeting complex, a preparation method thereof and an application of the targeting complex in tumor treatment. Background technique [0002] According to statistics from the Ministry of Health, malignant tumors have become the number one cause of death in my country. Conventional therapies for malignant tumors, including surgery, radiotherapy, and chemotherapy, all have certain limitations. For example, traditional anti-tumor drugs usually have relatively large side effects, and while killing cancer cells, they also cause great damage to normal cells. Targeted drugs use targeting molecules specific to tumor cells to specifically direct anti-tumor drugs to tumor cells, so they have higher killing efficiency on tumor cells and lower side effects on normal cells. The focus of pharmaceu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00A61K38/16A61P35/00
Inventor 郭占云王晓敏何胜祥
Owner SHANGHAI TONEKER BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com